COMPASS Pathways (CMPS) is back in focus after recent share price swings, with the mental health biotech drawing attention as ...

COMPASS Pathways stock was last at USD 11.90 on Nasdaq on October 2, 2026 at 4:00 p.m. ET, down 0.42 percent from USD 11.95.

Compass Pathways has already reported two positive phase 3 trials for treatment-resistant depression (TRD). The company's COMP360 synthetic psilocybin treatment could now be on a faster track for ...

COMPASS Pathways has been back in the spotlight, with fresh clinical data on its COMP360 psilocybin therapy and a sharply higher share price putting a simple question on the table. After such a move, ...

Compass Pathways (CMPS) is a UK-based biotech pioneering a new combination therapy for treatment resistant depression ("TRD") that involves administration of the psychedelic drug psilocybin - named ...

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that Compass granted equity awards ...

COMPASS Pathways stock (ISIN US20451W1018) stood at USD 13.75 in after-hours trading on Nasdaq on September 23, 2026, down ...

LONDON & NEW YORK--(BUSINESS WIRE)--Compass Pathways plc (Nasdaq: CMPS) (“Compass”), a biotechnology company dedicated to accelerating access to evidence-based innovation in mental health, today ...

Compass is a newly founded British company that is moving to commercialize the long-studied therapeutic impact of psilocybin. Both market acceptance issues and bad trip potential are risks of its ...

Participants received a single dose of either 25 mg of COMP360 or placebo On track for disclosure of top-line 6-week primary endpoint results in late June LONDON & NEW YORK--(BUSINESS WIRE)--Compass ...

Compass PathwaysCMPS stock surged Monday after President Donald Trump signed an executive order to ease the approval journey for psychedelic drugs. The order has two key elements. It provides a speedy ...

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced the appointment of Kelley Boucher as Chief ...